I think the same question was asked of the officials earlier this week. Maybe I could look at it from one side and then come back to your question.
But if you look at Bill C-22 and Bill C-91, which were about the restoration of patent protection for the innovative pharmaceutical industry to the same industry standards as every other industry in the country, we actually saw the fastest growth rate in R and D in the developed world. So we went from about $40 million a year to well in excess of $1 billion a year, showing that actually providing patent protection can attract investment.
Whether the specific of five coming through or three coming through will lead to a reduction in R and D, the challenge we face is the instability caused by uncertain IP protection. It does have impacts on our ability to track that investment globally.